Imugene Limited (AU:IMU) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Imugene Limited has announced the dosing of the first Australian patient in its Phase 1b trial of azer-cel, a promising allogeneic CAR T-cell therapy, at the Royal Prince Alfred Hospital in Sydney. This trial aims to offer a faster, off-the-shelf treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma, a challenging form of non-Hodgkin’s lymphoma. With successful results from US trials showing complete responses in patients, Imugene is optimistic about expanding the trial across Australia.
For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Benchmark Analysts Turn on Netflix (NASDAQ:NFLX)
- Ford (NYSE:F) Rolls out Best Sales Since 2019
- Intel (NASDAQ:INTC) Gears Up For CES
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
